Free Republic
Browse · Search
Bloggers & Personal
Topics · Post Article

Skip to comments.

FDA Terminates Hydroxychloroquine Emergency Authorization for COVID-19 despite therapeutic successes around the world, and significant usage by many doctors
Covexit ^ | 06/18/2020

Posted on 06/19/2020 7:52:31 AM PDT by SeekAndFind

Despite therapeutic successes with hydroxychloroquine around the world, and significant usage by many doctors in the US, who regularly report success in using the drug, and despite the support for the drug by the US president, the Food and Drugs Administration today revoked its emergency authorization for COVID-19.

The decision relies on “recent results from a large randomized clinical trial in hospitalized patients.”

UPDATE: It appears the announcement will not prevent prescriptions of HCQ outside hospital settings. Check this video:

FDA action today makes hcq MORE available to doctors and patients in outpatient setting. TREAT EARLY AND LIVE. ⁦Posted by Jack Russel on Monday, June 15, 2020

There is no reference to early treatment, where the therapy has been scientifically shown to work at IHU-Marseille, in Sao Paulo, and elsewhere.

Meanwhile, the competitor of hydroxychloroquine, remdesivir, remains authorized despite the absence of studies showing benefits in terms of mortality reduction.

See our previous reporting about how remdesivir was authorized.

Dr Fauci Announces Remdesivir to Become Standard of Care for COVID-19 while Chinese Study Finds it Ineffective; Other Research also Ignored

COVID-19 has already claimed over 100,000 lives in the US, and remains very active, with rising numbers of new infections in some 20 states.


See FDA Media Release

Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine

For Immediate Release:
June 15, 2020
Today, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. The agency determined that the legal criteria for issuing an EUA are no longer met. Based on its ongoing analysis of the EUA and emerging scientific data, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other potential serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use. This is the statutory standard for issuance of an EUA. The Biomedical Advanced Research and Development

Authority (BARDA) within the U.S. Department of Health and Human Services originally requested the EUA covering chloroquine and hydroxychloroquine, and the FDA granted the EUA on March 28, 2020 based on the science and data available at the time. Today, in consultation with the FDA, BARDA sent a letter to the FDA requesting revocation of the EUA based on up to date science and data.

“We’ve made clear throughout the public health emergency that our actions will be guided by science and that our decisions may evolve as we learn more about the SARS-CoV-2 virus, review the latest data, and consider the balance of risks versus benefits of treatments for COVID-19,” said FDA Deputy Commissioner for Medical and Scientific Affairs Anand Shah, M.D. “The FDA always underpins its decision-making with the most trustworthy, high-quality, up-to-date evidence available. We will continue to examine all of the emergency use authorizations the FDA has issued and make changes, as appropriate, based on emerging evidence.”

The FDA has a responsibility to regularly review the appropriateness of an EUA, and as such, the agency will review emerging information associated with the emergency uses for the authorized products. Recent results from a large randomized clinical trial in hospitalized patients, a population similar to the population for which chloroquine and hydroxychloroquine were authorized for emergency use, demonstrated that hydroxychloroquine showed no benefit on mortality or in speeding recovery. This outcome was consistent with other new data, including data showing that the suggested dosing regimens for chloroquine and hydroxychloroquine are unlikely to kill or inhibit the virus that causes COVID-19. The totality of scientific evidence currently available indicate a lack of benefit.

“While additional clinical trials continue to evaluate the potential benefit of these drugs in treating or preventing COVID-19, we determined the emergency use authorization was no longer appropriate. This action was taken following a rigorous assessment by scientists in our Center for Drug Evaluation and Research,” said Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation. “We remain committed to using every tool at our disposal in collaboration with innovators and researchers to provide sick patients timely access to appropriate new therapies. Our decisions will always be based on objective and rigorous evaluation of the scientific data.This will never change.”


Chloroquine and hydroxychloroquine are both FDA-approved to treat or prevent malaria. Hydroxychloroquine is also approved to treat autoimmune conditions such as chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid arthritis. Both drugs have been prescribed for years to help patients with these debilitating, or even deadly, diseases, and FDA has determined that these drugs are safe and effective when used for these diseases in accordance with their FDA-approved labeling. Of note, FDA approved products may be prescribed by physicians for off-label uses if they determine it is appropriate for treating their patients, including during COVID.


TOPICS: Government; Health/Medicine; Science; Society
KEYWORDS: covid19; fda; hcq; hydroxychloroquine
Navigation: use the links below to view more comments.
first previous 1-2021-22 last
To: Revel; All

Trumps narrative has been wrapped all around the axle, and committed since the beginning of all this.

Honestly cannot blame him, as Trump is neither doctor nor a walking molecular biology research library, and he is repeatedly provided access and advice from those who are supposed to be the “authorities” in any given field.

The problem, the government is literally one big immoral and corrupt power hungry machine, bent on total subjugation of our docile society.

Once Trump started repeating Fauci and Birx, and his narrative included how many people he saved by locking down the country and economy, he could not go back.

Its sick what these corrupt liars and murderers can and have done to us.


21 posted on 06/19/2020 9:59:31 AM PDT by patriotfury ((May the fleas of a thousand camels occupy mo' ham mads tents!))
[ Post Reply | Private Reply | To 14 | View Replies]

To: ican'tbelieveit

https://www.freerepublic.com/focus/bloggers/3857186/posts?page=16#16


22 posted on 06/19/2020 10:30:47 AM PDT by WildHighlander57 ((WildHighlander57 returning after lurking since 2000)
[ Post Reply | Private Reply | To 12 | View Replies]


Navigation: use the links below to view more comments.
first previous 1-2021-22 last

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
Bloggers & Personal
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson